Hypoxic regulation of angiogenesis by HIF-1

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 169-179

  Charlesworth, Philip J S ^a   Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

HIF 1; hypoxia inducible factor; hypoxic regulation; tumor associated macrophages; von Hippel Lindau protein

Indexed keywords

EID: 84885748822     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_15     Document Type: Chapter

References (125)

1. Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human eryth-ropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447-54 (1992).
2. Wang, G. L. & Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270, 1230-7 (1995).
3. Semenza, G. L. et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51, 553-5 (1997).
4. Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92, 5510-4 (1995).
5. Murre, C. et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58, 537-44 (1989).
6. Semenza, G. L., Koury, S. T., Nejfelt, M. K., Gearhart, J. D. & Antonarakis, S. E. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci USA 88, 8725-9 (1991).
7. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-40 (2001).
8. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydrox-ylation. Cell 107, 43-54 (2001).
9. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-8 (2001).
10. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-72 (2001).
11. Ruas, J. L., Poellinger, L. & Pereira, T. Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 118, 301-11 (2005).
12. Bracken, C. P., Whitelaw, M. L. & Peet, D. J. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci 60, 1376-93 (2003).
13. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9, 677-84 (2003).
14. Hirota, K. & Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59, 15-26 (2006).
15. Liu, L. & Simon, M. C. Regulation of transcription and translation by hypoxia. Cancer Biol Ther 3, 492-7 (2004).
16. Moeller, B. J., Cao, Y., Li, C. Y. & Dewhirst, M. W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5, 429-41 (2004).
17. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamy-cin-dependent signaling pathway. J Biol Chem 277, 27975-81 (2002).
18. Zhou, J., Schmid, T. & Brune, B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia induc-ible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol Biol Cell 14, 2216-25 (2003).
19. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F. & Maity, A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276, 9519-25 (2001).
20. Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57, 5328-35 (1997).
21. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. & Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-induc-ible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21, 3995-4004 (2001).
22. Blancher, C., Moore, J. W., Talks, K. L., Houlbrook, S. & Harris, A. L. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60, 7106-13 (2000).
23. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat Med 10, 789-99 (2004).
24. Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11, 293-9 (2001).
25. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-32 (2003).
26. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23, 9361-74 (2003).
27. Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25, 5675-86 (2005).
28. Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-55 (2002).
29. Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 277, 32405-8 (2002).
30. Kaelin, W. G., Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2, 673-82 (2002).
31. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L. & Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-305 (2000).
32. Leek, R. D., Harris, A. L. & Lewis, C. E. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 56, 423-35 (1994).
33. Leek, R. D. & Harris, A. L. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7, 177-89 (2002).
34. Murdoch, C., Giannoudis, A. & Lewis, C. E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-34 (2004).
35. Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-43 (1996).
36. Lewis, J. S., Landers, R. J., Underwood, J. C., Harris, A. L. & Lewis, C. E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 192, 150-8 (2000).
37. Burke, B. et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163, 1233-43 (2003).
38. Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42, 717-27 (2006).
39. Leek, R. D., Lewis, C. E. & Harris, A. L. The role of macrophages in tumour angiogenesis (ed. Bicknell R, L. C.) (Oxford University Press, 1997).
40. Talks, K. L. et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157, 411-21 (2000).
41. Krieg, M. et al. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-43 (2000).
42. Wykoff, C. C. et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60, 7075-83 (2000).
43. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-5 (1999).
44. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14, 34-44 (2000).
45. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14, 391-6 (2000).
46. Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-46 (2003).
47. Brahimi-Horn, M. C. & Pouyssegur, J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 242, 157-213 (2005).
48. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8, S62-7 (2002).
49. Bangoura, G., Yang, L. Y., Huang, G. W. & Wang, W. Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol 10, 525-30 (2004).
50. Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-68 (2002).
51. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. & Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6, 1335-40 (2000).
52. Maxwell, P. H. et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94, 8104-9 (1997).
53. Korkolopoulou, P. et al. Hypoxia-inducible factor 1alpha/vascu-lar endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30, 267-78 (2004).
54. Schindl, M. et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8, 1831-7 (2002).
55. Theodoropoulos, V. E. et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46, 200-8 (2004).
56. Birner, P., Schindl, M., Obermair, A., Breitenecker, G. & Oberhuber, G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7, 1661-8 (2001).
57. Birner, P. et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60, 4693-6 (2000).
58. Lidgren, A. et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11, 1129-35 (2005).
59. Giatromanolaki, A. et al. DEC1 (STRA13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhy-drase-9 overexpression in non-small cell lung cancer. J Pathol 200, 222-8 (2003).
60. Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85, 881-90 (2001).
61. Kim, S. J. et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49, 325-35 (2005).
62. Volm, M. & Koomagi, R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20, 1527-33 (2000).
63. Koukourakis, M. I. et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squa-mous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53, 1192-202 (2002).
64. Generali, D. et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12, 4562-8 (2006).
65. Koukourakis, M. I. et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24, 727-35 (2006).
66. Koukourakis, M. I. et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61, 1830-2 (2001).
67. Gustafsson, M. V. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9, 617-28 (2005).
68. Koshiji, M. et al. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. Embo J 23, 1949-56 (2004).
69. Hickey, M. M. & Simon, M. C. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 76, 217-57 (2006).
70. Weinstein, B. M. What guides early embryonic blood vessel formation? Dev Dyn 215, 2-11 (1999).
71. Liu, Y., Cox, S. R., Morita, T. & Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endo-thelial cells. Identification of a 5' enhancer. Circ Res 77, 638-43 (1995).
72. Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16, 4604-13 (1996).
73. Gerber, H. P., Condorelli, F., Park, J. & Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272, 23659-67 (1997).
74. Levy, N. S., Chung, S., Furneaux, H. & Levy, A. P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273, 6417-23 (1998).
75. Stein, I. et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 18, 3112-9 (1998).
76. Nikitenko, L. L., Fox, S. B., Kehoe, S., Rees, M. C. & Bicknell, R. Adrenomedullin and tumour angiogenesis. Br J Cancer 94, 1-7 (2006).
77. Garayoa, M. et al. Hypoxia-inducible factor-1 (HIF-1) up-regu-lates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14, 848-62 (2000).
78. Higgins, D. F. et al. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 287, F1223-32 (2004).
79. Hu, J., Discher, D. J., Bishopric, N. H. & Webster, K. A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 245, 894-9 (1998).
80. Grimshaw, M. J., Naylor, S. & Balkwill, F. R. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 1, 1273-81 (2002).
81. Grant, K., Loizidou, M. & Taylor, I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88, 163-6 (2003).
82. Grimshaw, M. J. et al. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 64, 2461-8 (2004).
83. Fan, S. et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-66 (2005).
84. Tacchini, L., De Ponti, C., Matteucci, E., Follis, R. & Desiderio, M. A. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25, 2089-100 (2004).
85. Maroni, P., Bendinelli, P., Matteucci, E. & Desiderio, M. A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-{kappa}B. Carcinogenesis 28, 267-79 (2007).
86. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-61 (2003).
87. Hara, S. et al. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol 42, 593-8 (2006).
88. Karashima, T. et al. Nuclear factor-kappaB mediates angiogen-esis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9, 2786-97 (2003).
89. Kim, K. S., Rajagopal, V., Gonsalves, C., Johnson, C. & Kalra, V. K. A novel role of hypoxia-inducible factor in cobalt chloride-and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol 177, 7211-24 (2006).
90. Sainson, R. C. & Harris, A. L. Hypoxia-regulated differentiation: let's step it up a Notch. Trends Mol Med 12, 141-3 (2006).
91. Shi, W. & Harris, A. L. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11, 41-52 (2006).
92. Rittling, S. R. & Chambers, A. F. Role of osteopontin in tumour progression. Br J Cancer 90, 1877-81 (2004).
93. Zhu, Y. et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24, 6555-63 (2005).
94. Le, Q. T. et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9, 59-67 (2003).
95. Schioppa, T. et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-402 (2003).
96. Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10, 858-64 (2004).
97. Ito, D. et al. Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24, 9456-69 (2004).
98. Yeung, H. Y. et al. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 146, 4951-60 (2005).
99. Lal, A. et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93, 1337-43 (2001).
100. Sanchez-Elsner, T. et al. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol 336, 9-24 (2004).
101. Schaffer, L. et al. Oxygen-regulated expression of TGF-beta 3, a growth factor involved in trophoblast differentiation. Placenta 24, 941-50 (2003).
102. Jones, N., Iljin, K., Dumont, D. J. & Alitalo, K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2, 257-67 (2001).
103. Yamakawa, M. et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93, 664-73 (2003).
104. Orend, G. & Chiquet-Ehrismann, R. Tenascin-C induced signaling in cancer. Cancer Lett 244, 143-63 (2006).
105. Lok, C. N. & Ponka, P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274, 24147-52 (1999).
106. Jones, D. T., Trowbridge, I. S. & Harris, A. L. Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 66, 2749-56 (2006).
107. Jacobson, K. A. & Gao, Z. G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5, 247-64 (2006).
108. Kong, T., Westerman, K. A., Faigle, M., Eltzschig, H. K. & Colgan, S. P. HIF-dependent induction of adenosine A2B receptor in hypoxia. Faseb J 20, 2242-50 (2006).
109. Coates, R. J., Weiss, N. S., Daling, J. R., Rettmer, R. L. & Warnick, G. R. Cancer risk in relation to serum copper levels. Cancer Res 49, 4353-6 (1989).
110. Martin, F. et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 105, 4613-9 (2005).
111. Lowndes, S. A. & Harris, A. L. The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia 10, 299-310 (2005).
112. Feldser, D. et al. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59, 3915-8 (1999).
113. Erler, J. T. & Giaccia, A. J. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66, 10238-41 (2006).
114. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-6 (2006).
115. Hurwitz, H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4 Suppl 2, S62-8 (2004).
116. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-42 (2004).
117. Belani, C. P. & Ramalingam, S. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer 6, 267-8 (2005).
118. Kerr, C. Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol 6, 266 (2005).
119. Lau, S. C., Rosa, D. D. & Jayson, G. Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr Opin Mol Ther 7, 493-501 (2005).
120. Kane, R. C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12, 7271-8 (2006).
121. Sun, X. et al. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8, 638-45 (2001).
122. Sun, X. et al. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther 13, 428-35 (2006).
123. Moeller, B. J. et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8, 99-110 (2005).
124. Yeo, E. J. et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95, 516-25 (2003).
125. Semenza, G. L. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 10, 267-80 (2006).